Contrast Media Market Report 2026

Contrast Media Market Overview

• Contrast Media market size has reached to $4.82 billion in 2025 • Expected to grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 4.7% • Growth Driver: Rising Utilization Of Diagnostic Procedures Accelerates Growth In The Contrast Media Market Insights From NHS Statistics • Market Trend: Strategic Partnership Revolutionize The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Contrast Media Market?

Contrast media refer to the chemical agents or contrast media that increase the contrast of structures of fluids in the body by improving the contrast resolution of an imaging modality. It is used to enhance and increase the quality of images (or pictures) that helps radiologist to report on how the body is functioning and whether there is any disease or anomaly. The main types of contrast media are barium-based contrast media, iodinated contrast media, gadolinium-based contrast media, and microbubble contrast media. Microbubbles contrast media are intravenous contrast agents used in contrast-enhanced ultrasound. The route of administration is an intravascular route, oral route, rectal route, and other routes of administration, which are modalized in X-Ray or CT, MRI, and ultrasound. The various indications involved cardiovascular disease, oncology, gastrointestinal disorders, neurological disorders, and other indications, that are used in hospitals and clinics.

What Is The Contrast Media Market Growth Forecast?

The contrast media market size is expected to see steady growth in the next few years. It will grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing investments in precision diagnostics, rising demand for early disease detection, expansion of outpatient imaging centers, growing adoption of ai-assisted imaging analysis, increasing focus on safer contrast formulations. Major trends in the forecast period include increasing use of contrast media in diagnostic imaging, rising demand for advanced mri and ct scans, growing adoption of non-ionic contrast agents, expansion of image-guided diagnostic procedures, enhanced focus on patient safety and imaging accuracy.

What Is The Driver Of The Contrast Media Market?

The increased use of diagnostic procedures is expected to propel the growth of the contrast media market in the coming years. Diagnostic procedures are medical tests, exams, or processes conducted by medical professionals to determine the presence, degree, and type of disease, condition, or damage in a patient. Contrast media are important in diagnostic techniques because they highlight certain locations or structures inside the body, allowing healthcare practitioners to make precise diagnoses and educated choices regarding therapy. For instance, in November 2024, according to NHS, a U.K.-based government agency, in March 2024, 47.2 million imaging tests were reported in England compared with 45.0 million in the previous year, an increase of 4.8%. Further, plain radiography (X-ray) was most common with 22.6 million procedures (up 2.6% from 2022-2023), followed by diagnostic ultrasonography (ultrasound, 10.9 million, up 5.9%), computerized axial tomography (CT scan, 7.7 million, up 8.4%), and magnetic resonance imaging (MRI, 4.4 million, up 8.1%). Therefore, the increased use of diagnostic procedures is driving the contrast media industry.

Key Players In The Global Contrast Media Market

Major companies operating in the contrast media market are Bayer AG, Bracco Imaging S.p.A., GE Healthcare, Guerbet Group, Lantheus Medical Imaging, Inc., Daiichi Sankyo Company, Ltd., Fujifilm Holdings Corporation, Beijing Beilu Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co., Ltd., NanoPET Pharma GmbH, Spago Nanomedical AB, Medtron AG, Ulrich GmbH & Co. KG, JB Pharma (Jodas Expoim Pvt. Ltd. – as manufacturer), Onko İlaç Sanayi ve Ticaret A.S., Chemco Innovative Chemie Pvt. Ltd., Gliesse Pharmaceuticals, Nantong Jinghua Pharmaceutical Co., Ltd., ST Pharm Co. Ltd., Troikaa Pharmaceuticals Ltd., MBA Pharmaceuticals Pvt. Ltd., ArcherChem Healthcare Limited, Biophore Pharma Inc., Subhra Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd.

Global Contrast Media Market Trends and Insights

Major companies operating in the contrast media market are adopting a strategic partnership approach to provide breast imaging facilities with a complete contrast-enhanced mammography package. Strategic partnerships refer to a process in which companies leverage each other’s strengths and resources to achieve mutual benefits and success. For instance, in September 2023, Hologic Inc., a US-based healthcare technology company, announced a partnership with Bayer AG, a Germany-based biotechnology and pharmaceutical company, to provide contrast-enhanced mammography (CEM) technologies to increase breast cancer diagnosis in many countries spanning Europe, Canada, and Asia Pacific. CEM is a highly sensitive, inexpensive breast imaging technique that combines computerized mammography with the injection of a contrast agent to aid in the detection of breast cancer and guide treatment options. The collaboration combines the businesses' premier technology (Hologic mammography gantries and Bayer CEM-approved injectable devices) to enable contrast media delivery during a mammography test. Bayer and Hologic want to serve radiologists and their teams' requirements with the new arrangement by delivering a whole product bundle and the hands-on training required for successfully adopting CEM into their facility's workflow.

What Are Latest Mergers And Acquisitions In The Contrast Media Market?

In February 2023, Bracco Imaging S.p.A., an Italy-based provider of contrast media and diagnostic imaging agents, acquired the remaining 49% stake in Bracco‑Eisai Co. Ltd. for an undisclosed amount. Through this acquisition, Bracco Imaging aims to gain full control over its Japanese operations, streamline the production and regulatory approval of MRI contrast agents, and strengthen its global contrast media portfolio. Bracco‑Eisai Co. Ltd. is a Japan-based company that provides MRI contrast media.

What Defines the Contrast Media Market?

The contrast media market consists of sales of Di meglumine injection, iodine-based contrast materials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Contrast Media Market Report 2026?

The contrast media market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the contrast media industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.